Research information only, not medical advice. Survodutide (BI 456906) is an investigational once-weekly injectable dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim (with Zealand Pharma) for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is not approved by the FDA; it is in phase 3 development (the SYNCHRONIZE programme) and holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate to advanced fibrosis.
Survodutide at a glance
The evidence base consists of randomised controlled trials in obesity and metabolic liver disease. In the phase 3 SYNCHRONIZE-1 trial (adults with overweight or obesity without type 2 diabetes), survodutide produced a mean weight loss of up to about 16.6% at 76 weeks versus 3.2% with placebo, per Boehringer Ingelheim's 2026 topline announcement. A separate phase 3 trial in metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD) reported positive results in 2026. Survodutide remains investigational and is not approved for any use.
See how we grade evidence for the methodology behind this page.
Evidence profile
70 studies- Human RCT 15 · 21%
- Human trial 7 · 10%
- Review 29 · 41%
- Animal 11 · 16%
- In-vitro 6 · 9%
- Unknown 2 · 3%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
Clinical trials
-
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
-
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
-
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
-
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
-
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
-
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
-
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
-
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
-
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
-
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
-
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
-
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
-
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
-
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
-
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
-
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
-
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body
-
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body
-
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
-
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
-
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
-
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Indexed research
Sorted by evidence level, strongest first.
- Human RCT 2026Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
This post hoc analysis of two phase 2 trials found that survodutide improved biomarkers of beta-cell function and insulin sensitivity in people with type 2 diabetes or overweight/obesity, with effects largely independent of body weight changes.
- Human RCT 2026Survodutide Once Weekly for the Treatment of Adults with Obesity
This phase 3 double-blind trial found that survodutide, a glucagon receptor-GLP-1 receptor dual agonist, led to significantly greater weight reduction than placebo in adults with obesity without diabetes over 76 weeks.
- Human RCT 2026Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
This phase 3 trial found that survodutide significantly reduced liver fat content and body weight in adults with obesity and metabolic dysfunction-associated steatotic liver disease compared to placebo.
- Human RCT 2026Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial
The SYNCHRONIZE-JP trial is a phase 3, randomized, double-blind, placebo-controlled study evaluating survodutide for obesity in Japanese adults, with baseline characteristics reported.
- Human RCT 2026Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial
The study describes baseline characteristics of participants in the SYNCHRONIZE cardiovascular outcomes trial evaluating survodutide for obesity.
- Human RCT 2026Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
- Human RCT 2026Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
- Human RCT 2024Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
- Human RCT 2025Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial
This letter reports a post hoc analysis of a randomized controlled trial showing that Survodutide, a dual glucagon and GLP-1 receptor agonist, improves blood pressure in adults with obesity.
- Human RCT 2023A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity
+ 60 more studies indexed for Survodutide.
Frequently asked questions
- Is Survodutide approved for human use?
- Survodutide (BI 456906) is an investigational once-weekly injectable dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim (with Zealand Pharma) for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is not approved by the FDA; it is in phase 3 development (the SYNCHRONIZE programme) and holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate to advanced fibrosis.
- What does the research on Survodutide show?
- The evidence base consists of randomised controlled trials in obesity and metabolic liver disease. In the phase 3 SYNCHRONIZE-1 trial (adults with overweight or obesity without type 2 diabetes), survodutide produced a mean weight loss of up to about 16.6% at 76 weeks versus 3.2% with placebo, per Boehringer Ingelheim's 2026 topline announcement. A separate phase 3 trial in metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD) reported positive results in 2026. Survodutide remains investigational and is not approved for any use.